News Related to Psychedelic-Assisted Therapy

Related coverage linked through entity extraction aliases.

Psyence Biomedical Doses First Patient in Phase IIb NPX-5 Trial

Apr 24, 2026

Psyence Biomedical dosed the first patient in a Phase IIb study of NPX-5 in Adjustment Disorder among cancer patients receiving palliative care. The randomized, double-blind trial is running across five Australian sites.

Studies point to new psychedelic-based depression treatments

Apr 12, 2026

New findings on psychedelic-based depression treatments included a UK DMT trial in 34 adults and a mouse study of modified psilocin compounds with fewer hallucinogenic-like effects.